Paper Details

  1. Home
  2. Paper Details

Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.

Author: CaiJian-Ping, HuGuo-Xin, LiYing-Hui, LinDong-Dong, LinQian-Meng, LiuQian, LuXiang-Ran, MaYa-Qing, Ou-YangQiu-Geng, XuRen-Ai

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the catalytic activities of 27 CYP3A4 variants on saxagliptin metabolism in vitro. Most variants showed decreased metabolic activity compared to wild-type CYP3A4.1, suggesting that genetic polymorphisms in CYP3A4 may influence saxagliptin metabolism and potentially affect drug efficacy and safety.
Paper Details　
Original Abstract of the Article :
Saxagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor widely used in patients with type 2 diabetes. It can increase the amount of insulin after meals and lower blood sugar. CYP450 3A4 (CYP3A4) can metabolize about 30%-40% of therapeutic drugs. Individual differences caused by CYP3A4 genetic poly...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/fcp.12693

データ提供：米国国立医学図書館（NLM）

Saxagliptin Metabolism: A Tale of Individual Differences

Saxagliptin, a drug used to treat type 2 diabetes, relies on the enzyme CYP3A4 for its metabolism. This research explores the impact of genetic variations in CYP3A4 on saxagliptin metabolism. The study investigated the catalytic activity of 27 CYP3A4 variants on saxagliptin metabolism in vitro, aiming to understand how individual differences in CYP3A4 can influence drug efficacy and safety.

Individualized Drug Use: Tailoring Treatment to Genetic Profiles

The study found that different CYP3A4 variants exhibit significant variations in their ability to metabolize saxagliptin. This finding emphasizes the importance of considering individual genetic profiles when prescribing saxagliptin, potentially allowing for more personalized and effective treatment regimens.

Personalized Medicine: A New Era in Drug Therapy

This research highlights the growing importance of personalized medicine, where treatment decisions are tailored to individual genetic profiles. The study encourages further research to explore the clinical implications of CYP3A4 variants on saxagliptin metabolism, ultimately paving the way for more precise and effective drug therapies.

Dr.Camel's Conclusion

Imagine a camel caravan traveling through a desert, encountering a diverse landscape with varying terrain and obstacles. This research explores the unique metabolic pathways of saxagliptin, revealing that just as each camel in the caravan might face different challenges, individuals can metabolize saxagliptin differently. Understanding these individual variations is crucial for optimizing treatment, ensuring a smoother and more successful journey through the desert of diabetes management.

Date :
  1. Date Completed 2022-01-17
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

33961299

DOI: Digital Object Identifier

10.1111/fcp.12693

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.